Skip to main content

Advertisement

ADVERTISEMENT

News

Rheacell

https://clinicaltrials.gov/study/NCT06489028

A 250-patient study will investigate the efficacy and safety of allo-APZ2-CVU administered topically for treatment of non-healing venous ulcers with the primary outcome of complete wound closure at 18 weeks. Not yet recruiting; estimated study completion is Sept 2027. clinicaltrials.gov

Advertisement

Advertisement

Advertisement